Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model
Open Access
- 12 October 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10), e0140273
- https://doi.org/10.1371/journal.pone.0140273
Abstract
Reactive cardiac fibrosis resulting from chronic pressure overload (PO) compromises ventricular function and contributes to congestive heart failure. We explored whether nonreceptor tyrosine kinases (NTKs) play a key role in fibrosis by activating cardiac fibroblasts (CFb), and could potentially serve as a target to reduce PO-induced cardiac fibrosis. Our studies were carried out in PO mouse myocardium induced by transverse aortic constriction (TAC). Administration of a tyrosine kinase inhibitor, dasatinib, via an intraperitoneally implanted mini-osmotic pump at 0.44 mg/kg/day reduced PO-induced accumulation of extracellular matrix (ECM) proteins and improved left ventricular geometry and function. Furthermore, dasatinib treatment inhibited NTK activation (primarily Pyk2 and Fak) and reduced the level of FSP1 positive cells in the PO myocardium. In vitro studies using cultured mouse CFb showed that dasatinib treatment at 50 nM reduced: (i) extracellular accumulation of both collagen and fibronectin, (ii) both basal and PDGF-stimulated activation of Pyk2, (iii) nuclear accumulation of Ki67, SKP2 and histone-H2B and (iv) PDGF-stimulated CFb proliferation and migration. However, dasatinib did not affect cardiomyocyte morphologies in either the ventricular tissue after in vivo administration or in isolated cells after in vitro treatment. Mass spectrometric quantification of dasatinib in cultured cells indicated that the uptake of dasatinib by CFb was greater that that taken up by cardiomyocytes. Dasatinib treatment primarily suppressed PDGF but not insulin-stimulated signaling (Erk versus Akt activation) in both CFb and cardiomyocytes. These data indicate that dasatinib treatment at lower doses than that used in chemotherapy has the capacity to reduce hypertrophy-associated fibrosis and improve ventricular function.Keywords
This publication has 47 references indexed in Scilit:
- SPARC regulates collagen interaction with cardiac fibroblast cell surfacesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Phosphorylation of Histone H2B Serine 32 Is Linked to Cell TransformationJournal of Biological Chemistry, 2011
- Lack of β3 Integrin Signaling Contributes to Calpain-Mediated Myocardial Cell Loss in Pressure-Overloaded MyocardiumJournal of Cardiovascular Pharmacology, 2010
- Regulation of pro‐inflammatory and pro‐fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytesJournal of Cell Communication and Signaling, 2010
- Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological PreventionJNCI Journal of the National Cancer Institute, 2010
- β 3 Integrin‐mediated ubiquitination activates survival signaling during myocardial hypertrophyThe FASEB Journal, 2009
- Pressure Overload–Induced Alterations in Fibrillar Collagen Content and Myocardial Diastolic FunctionCirculation, 2009
- Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer TherapeuticsCirculation, 2008
- In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardiumAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008